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Over the past two decades, overdose deaths involving pharmaceuticals, heroin and, more            
recently, synthetic opioids such as illicitly manufactured fentanyl have increased in the United             
States. Connecticut has one of the highest opioid-involved mortality rates when compared to             
other states, and between 2009 and 2017, the incidence of opioid-involved fatal overdoses in              
Connecticut increased by about 350%. We examined opioid-involved fatality data from the            
Connecticut Office of the Chief Medical Examiner ​over a 9-year period, from ​January 1st, 2009               
and December 31st, 2017, to better understand the granular spatiotemporal trends of the crisis              
within CT with an eye toward informing public health overdose prevention and treatment             
strategies.  
The epidemiology of fatal opioid-involved overdoses in Connecticut exhibits distinct spatial, 
demographic, and temporal patterns. The recent increase in overdose deaths is driven by fentanyl 
and fentanyl analogues. Although much of the crisis has impacted white, non-Hispanic people, 
the burden on black, non-Hispanic and Hispanic, White populations continues to grow and 
outpace that of the white, non-Hispanic population. Additionally, fatalities among males are 
outpacing fatalities among females. Thus, future interventions ought to focus on preventing 










Background. ​Unintentional opioid-involved overdose fatality rates have increased about 350% 
in Connecticut from 2009 to 2017, inciting a considerable statewide public health crisis. Several 
breeds of opioids have given rise to these overdose deaths, including pharmaceutical opioid 
analgesics, illicit opioids like heroin and fentanyl. The objective of this study is to to 
descriptively assess the temporal and spatial trends in opioid-involved overdose deaths in 
Connecticut between January 1st, 2009 and December 31st, 2017.  
Methods. ​Using data extracted from the Connecticut Office of the Chief Medical Examiner 
database, rates of opioid-involved overdose death --for which injury occurred in Connecticut 
between 2009 and 2017--  were calculated. Spatial and temporal trends in opioid-involved 
fatalities were evaluated, including descriptive statistics on age, race/ethnicity, type(s) of opioids 
present, the presence of other drugs in the toxicological report, and whether injection was 
suspected to have been involved in the fatality. Emerging hot spot analysis was used for 
spatiotemporal analysis.  
Results. ​From January 1, 2009 to December 31, 2017, we identified 4,547 victims of fatal 
opioid-involved overdose which occurred in Connecticut. The rate of deaths involving an opioid 
of any type increased from 7.62 to 26.86 per 100,000 people from 2009 to 2017 and increased 
from 0.4 to 18.6 per 100,000 people in the same period for those involving fentanyl. The number 
of cases that involved fentanyl or a fentanyl analogue as the only opioid present at time of death 
have increased over time whereas pharmaceutical-only deaths have steadily decreased during the 
same period. Across all years and after adjusting for population size, victims were consistently 
more male than female, and more white (non-Hispanic) than any other race when adjusting for 
population size. Cases were concentrated in the 25 to 44 age group for all years with a bimodal 
distribution, including peaks near ages 25 and 45. While the majority of fatalities in 2009 and 
2010 included only pharmaceuticals, heroin-only deaths dominated from 2011 to 2015. In 2016 
and 2017, most deaths were attributed to a combination of opioid types, including fentanyl, 
heroin, and pharmaceuticals.  The crisis has become more fentanyl-driven over time, with an 
increase from 0.4 to 18.6 per 100,000 population of fentanyl-involved deaths from 2009 to 2017. 
In Connecticut, cases are most concentrated in urban areas by both raw total and when adjusted 
for population size. Among only fentanyl-involved deaths, victims were predominantly male 
(79.1%) with 54.5% of victims aged between 25 and 44 (38.3% aged 34 or under).  
Conclusions. ​The recent increase in opioid-involved deaths during the studied 9 years is 
attributed to the expanded availability of fentanyl and fentanyl analogues. This corresponds to 
the growing supply and use in the United States of illicitly manufactured fentanyl. Additionally, 
there are distinct spatial patterns to the crisis; interventions ought to account for the distinct 






Since 2000, overdose deaths involving pharmaceuticals, heroin and, more recently, synthetic 
opioids such as illicitly manufactured fentanyl (IMF) have increased in the United States ​(Rudd 
et al. 2016)​. Situated in the Northeast, where much of the opioid crisis has taken its toll, 
Connecticut has one of the highest opioid-involved (OI) mortality rates when compared to other 
states (CDC, 2018). We examined OI fatality data from the Office of the Chief Medical 
Examiner (OCME) ​over a 9-year period, from ​January 1st, 2009 and December 31st, 2017, to 
better understand the granular spatiotemporal trends of the crisis within CT. The purpose of this 
study is to better understand how the opioid crisis is evolving and who ought to be targeted by 
future interventions.  
2. Background 
2.1 Opioid Crisis in the United States 
Fatal overdose has become a significant public health issue in the United States (US), where 
between 1999 and 2017, over 700,000 individuals died from a drug overdose (CDC, 2019). The 
proportion of fatal overdoses which involve an opioid has increased during this time period, with 
approximately 6 times greater OI deaths in 2017 than in 1999 (CDC, 2019). On average, 130 
Americans die from an OI overdose per day (WONDER, 2017).  
 
The emergence of the current overdose crisis is often attributed an increase in opioid prescribing 
beginning in the 1990s ​(Kolodny et al. 2015)​. The Centers for Disease and Prevention (CDC) 
considers the early increase in pharmaceutical-involved fatal overdoses a “first wave” in a series 
of three waves in the crisis.  
 
Prescription opioid abuse is a significant risk factor for initiating heroin use (Rudd et al., 2016a), 
as studies have shown that heroin initiation is often preceded by prescription opioid use, up to 
75% of the time  (Cicero et al., 2014; Mars et al., 2014). The transition from pharmaceuticals to 
heroin is often due to the cheaper price and greater availability of heroin when compared to 
prescriptions, particularly after over-prescribing was recognized as a problem (McGreal, 2016). 
Additionally,​ abuse-deterrent reformulations of pharmaceutical opioids began to appear around 
2010 at the instigation of the FDA (Evans, 2018).  
 
The opioid crisis accelerated in 2010 with an increase in heroin-involved deaths, which has been 
termed the “second wave” of the epidemic by the CDC. Between 2011 and 2013, the rate of 
heroin-involved overdose deaths in the US increased by almost 200%, from 1.4 per 100,000 to 




The most recent and most deadly wave of the opioid crisis commenced in 2013 and has been 
attributed to synthetic opioids like IMF (CDC, 2018; Hedegaard et al., 2017; Rudd et al., 2016b). 
It is worth distinguishing between pharmaceutical fentanyl and IMF at this juncture; both are 
extremely powerful analgesics, but pharmaceutical fentanyl is produced legitimately in the US, 
while IMF is often produced in and shipped from China. It is often pressed into pill form or 
mixed into the heroin supply. In 2016, approximately 35 times more fentanyl was seized 
compared to 2013 (Knierim, 2018).  
 
National agencies have endeavored to reduce morbidity and mortality associated with the opioid 
crisis. These efforts have included placing limits on opioid prescriptions (Chua, 2019), 
improving awareness of and access to opioid antagonists like naloxone, and improving access to 
various types of treatment. In 2016, the Obama administration committed to address the crisis 
and Congress provided $1 billion in grants to states for these efforts (White House, 2016). In 
October 2017, President Trump declared that the opioid epidemic had become a national 
emergency, and two funding bills were subsequently passed (White House, 2018). The Trump 
Administration has stated that as of late 2018, they had secured $6 billion in funding to fight 
opioid abuse; these efforts have been focused on a “Safer Prescribing Plan” to reduce opioid 
prescribing, as well as securing the borders against smuggling (White House, 2018). 
 
2.2 Opioid Crisis in Connecticut 
Connecticut has not been spared from this US public health crisis,​ experiencing one of the 
highest rates of increase in synthetic opioid deaths (125.9% from 2014 to 2015) when compared 
to other states; during this same time period, neighboring New York saw an increase of 135.7%, 
and Illinois had the next highest with an increase of 120% ​(Rudd et al. 2016)​.  
 
The age-adjusted death rate opioid overdose in Connecticut increased from 3.9 to 23.3 from 1999 
to 2016 per 100,000 population in Connecticut (CDC, 2017). In fact, Connecticut had the eighth 
highest age-adjusted opioid overdose death rate in the US in 2016 (CDC, 2017). 
 
Although it seems the opioid crisis is “leveling off” in Connecticut according to the Chief 
Medical Examiner, (O’Neill, 2010), it is still recognized as a serious issue in the state. In early 
April 2019, Governor Ned Lamont announced a new statewide awareness campaign and a new 
application supported by the Connecticut Department of Health to support access to the opioid 





Although there is some talk of the crisis ebbing (Alonso-Zaldivar, 2018), it seems fentanyl is still 
on the upswing and there is plenty of room for more insight. More research is required to 
understand the granular spatiotemporal details of the crisis, as much of the research by the CDC 
is aggregated to large regions.  
 
With that in mind, the purpose of this paper is to describe the epidemiology of fatal opioid 
overdoses in Connecticut from 2009 to 2017 by identifying demographic factors, spatial and 
temporal patterns, opioid type detected in toxicology, as well as concomitant identified in 
toxicology. Results will shed light on how the crisis unfolded in Connecticut during the study 
period.  
 
2.3 Previous Findings 
There is a wealth of literature regarding the recent opioid crisis, including a 2011 analysis of OI 
deaths in Connecticut (1997-2007) using Connecticut OCME data, which found that total 
heroin-involved deaths were relatively stable across the study period and total OI deaths 
(including pharmaceuticals) were increasing over time ​(Green et al. 2011)​. Since even the newest 
data included in that analysis is over a decade old, it is prudent to take another look at fatal 
opioid intoxications in Connecticut, as the number of overdoses annually has increased 
significantly since that time and the ratio of opioid types has shifted.  
 
A more recent publication using data from the Connecticut OCME, focused on 2016, ​established 
that targeting by opioid type is needed ​(Clinton et al. 2019)​. Clinton et al showed that the 
younger population tends towards illicit opioids (under 44), while those aged 45 and older are 
more likely to overdose as a result of pharmaceutical opioids; thus, specialized approaches are 
needed. However, their analysis is limited in scope to one calendar year.  
  
To our knowledge, there has not yet been an effort to spatiotemporally evaluate Connecticut’s OI 
fatality data in recent years to this level of detail and over a several-year timespan. This paper 
will fill that gap.  
3. Methods 
3.1 Data Source 
All physicians, funeral directors, law enforcement officers, and other officials are required by 
law to notify the OCME of any reportable death (OCME, 2009). A reportable death is defined as 
a death which is subject to investigation by the Chief Medical Examiner, which includes 
accidents, homicides, suicides, and other deaths which are sudden or unexpected. Approximately 
half of all deaths which occur in Connecticut are reportable, as the criteria are designed to be 
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“broad, overlapping, and inclusive” (OCME, 2006). Therefore, we expect that the OCME 
database includes all OI deaths which have occurred in Connecticut and does not underestimate 
the reach of this crisis (Grau, personal communication). 
 
After the investigation is finalized by the medical examiner, several variables are available to be 
extracted from the OCME database, including dates of birth and death, addresses for injury 
location, residence, and death location, toxicological results, narrative and investigation records,  
a ​post-mortem report​ (autopsy), ​photographic evidence, and a death certificate which lists the 
manner of death (MOD) and the cause of death (COD). 
 
Both MOD and COD are listed on a death certificate and they are not interchangeable. MOD is a 
way to categorize all deaths into general categories; the options are: natural, accidental, suicide, 
homicide and undetermined. For some cases, MOD is temporarily listed as “Pending” while 
evidence is collected. COD is a more specific way to describe the injury that caused death, and in 
the case of drug overdose, they often list the drugs which were present in the toxicology results. 
 
3.2 Data Collection & Case Selection 
 
These data were collected at the OCME in Farmington, Connecticut. The January 1st, 2017 to 
December 31st, 2017 data were collected by Natalee Desotell and Dr. Lauretta Grau in 2018 and 
2019, while earlier data were collected either by Dr. Lauretta Grau or individuals under her 
supervision.  
 
There are several salient differences between our gathered data and those released by the 
Connecticut Department of Health (DPH) and available online. The latter report accidental death 
data only and begin in 2012 (CT Open Data, 2019). Our data includes both accidental and 
undetermined deaths (70 additional cases) and thereby provides a possible upper and lower 
bound to the actual number of OI deaths (Grau, personal communication).  
 
Cases with a MOD of either undetermined or accidental were kept in the dataset. Of these 
accidental and undetermined cases, we selected all which were likely to be OI based on review 
of the COD.  
 
All available toxicology reports were reviewed for the presence of opioids and other substances, 
including ​only those with quantifiable results (i.e., we do not include screening data unless the 
ME chose to use those data in identifying the COD). ​There is no toxicological test specific for 
heroin, and the presence of this opioid was based upon either the presence of 
6-monoacetylmorphine (a heroin metabolite) or medical examiner’s determination of the COD.  
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For rare cases with no toxicology report (55 cases, 1.2%) or ​post-mortem report​ (35 cases, 
<1.0%), we relied on the COD as diagnosed by the medical examiner to confirm that an opioid 
was involved. A common reason for the absence of a toxicology report was when the deceased 
had been hospitalized, no biological samples were available from the time of admission, and an 
extended period of time then elapsed between time of injury and death. Occasionally, no 
post-mortem report​ was performed for religious reasons. In such cases, we deferred to the 
medical examiners’ decisions concerning the COD when they based it upon hospital screening 
tests, history at admission, and their clinical expertise. In all, no more than 5% of any variable 
had missing or unknown data. 
 
Most cases had three associated addresses (residence, injury, and death). A “best” address of the 
three was selected for purposes of geospatial analysis. The injury location was used when 
available (4329, 95.2%). If injury was not available, the residence address was used (194, 4.2%). 
As a last resort, the death location (often a hospital) was used (24, 0.5%). The rationale for using 
the death address as a last resort was that, although it is likely within driving distance of the 
injury site, the location where a person was pronounced dead may have no bearing on where they 
used drugs. 
 
For the purpose of this study, we classified race/ethnicity as white, non-Hispanic (W-NH); black, 
non-Hispanic (B-NH); white, Hispanic (W-H); and other/unknown (O-U). The other/unknown 
category was made up of victims whose race was unknown or who was part of a racial/ethnic 
group which had under 25 total cases.  
 
Each of our cases was categorized into one of four categories: “fentanyl only”, “heroin only”, 
“pharmaceutical only”, or “combination”. A case was regarded as “fentanyl only” if toxicology 
indicated the presence of fentanyl or a fentanyl analogue, but no heroin or pharmaceuticals. 
“Heroin only” cases included heroin metabolites, but no pharmaceuticals or fentanyl. A case was 
considered “pharmaceutical only” if pharmaceutical drugs alone were detected. In a case when 






Figure 1. Flowchart of Case Selection From Pool of All OCME Cases. ​Total OCME cases and accidental and undetermined 
totals were collected from OCME Calendar Year Statistics (OCME, 2018), available publicly online; *From 2009 to 2016, some 
selection was performed by the OCME Information Technology Analyst by querying specific terms, including 
6-monoacetylmorphine, heroin, oxycodone and words such as toxicity, poisoning, and overdose. From that comprehensive list, 
cases which did not involve opioids or were ruled to be the result of a motor vehicle accident or fall were eliminated. For 2017, 
we were given the full list of all deaths and performed all case selection. We believe the possibility of bias is minimal because of 
the over-inclusiveness of the queries in the earlier years.; †Cases were omitted if the injury address was outside Connecticut (n = 
21). For unknown injury addresses, injury was assumed to be within Connecticut if the residential location was in Connecticut.  
 
The final sample of 4,547 cases included all accidental and undetermined OI deaths between 
January 1, 2009 and December 31, 2017. ​All data for the final sample were verified against the 
source documents which included the final death certificate, external exam section of the 
post-mortem report, a case narrative consisting of the report and investigation completed when 





A space-time cube and emerging hot spot analysis was applied to the data in ArcGIS to evaluate 
the spatiotemporal trends. A space-time cube is a data structure that divides space into equal 
sections which can be visualized as a 3D cube. The x-y direction of the cube represents physical 
space, and that geographic area is then separated into equally sized “bins”. The z (or vertical 
height) direction of the cube represents time. Time is also separated into equally sized “bins”, 
such as weeks, months, or years (Kang et al, 2018). After applying an emerging hot spot analysis 
to the space-time cube data structure, it’s possible to visualize how trends vary across both space 
and time.  
 
Specific incidence rates were computed by sex, age, and race/ethnicity by dividing the raw total 
of OI deaths by the total population at risk (CT DPH, 2019). 
 
Descriptive figures were created in ​RStudio version 1.0.143, and spatial visualizations were 
created in ArcGIS version 10.4.1 with a little assistance from Adobe Illustrator. ​Location data 
were geocoded using Texas A&M University’s batch geocoder, which returned a match score 
representing the confidence in the result (​TAMU GeoServices, 2019​). For all match scores below 
95 (under 10% of all addresses, typically due to a misspelling), a coordinate search was 
performed using Google Maps.  
4. Results 
Between 2009 and 2017, 4,547 OI deaths occurred in Connecticut. Of those, 55% occurred 










4.1 Age Distribution 
Across all years, the most represented age group was 25 to 44, which made up nearly half of all 
victims at 49.4% (Table 1).  
 
While the OI deaths in the 15-24 age group remained relatively stable across the study period, 
ages 25 and older made up the bulk of the increase in OI fatalities (Figure 3). The 55+ age group 
saw the largest increase in death rate from 2009 to 2017; fatalities aged 55-64 increased by about 




Figure 3. Opioid-Involved Deaths by Age Group.  
 
All age groups aged 15 and up demonstrated a rise in fentanyl-involved (FI) overdoses, with the 
initial increase beginning around 2013 and sharply accelerating for ages 25 to 44 in 2015 (Figure 
4). Since the onset of the fentanyl crisis in 2013 to 2017, ages 44 and under experienced the 
largest death rate increase. The death rate for the 34 and under age group increased by over 3 




Figure 4. Fentanyl-Involved Deaths by Age Group 
 
The mean and median age at death consistently hover around age 40, with a standard deviation 
between 11 and 13. The first two modes for each year provide some insight into the bimodal 
nature of the age data.  
 
Table 2: Measures of Central Tendency for Age at Death. 
 Mean (SD) Median 1st Mode 2nd Mode 
2009 39.7 (11.3) 40.0 42.0 29.0 
2010 40.9 (11.0) 43.0 44.0 46.0 
2011 38.6 (12.1) 38.0 29.0 28.0 
2012 40.0 (12.7) 40.0 29.0 31.0 
2013 40.8 (12.4) 42.0 44.0 26.0 
2014 41.0 (11.9) 41.0 44.0 35.0 
2015 42.0 (12.9) 42.0 55.0 28.0 
2016 41.7 (12.2) 42.0 33.0 31.0 
2017 41.2 (12.2) 39.5 33.0 31.0 
All 41.0 (12.2) 41.0 29.0 44.0 
 
Fatal overdose data for age at death in Connecticut is not normally distributed. Instead, it’s 
necessary to view a frequency distribution to understand the true nature of the age data. A 
frequency distribution reveals that for all OI deaths, each year exhibits a bimodal age distribution 
with one peak around age 25 and another peak near age 45 (Figure 5). This is consistent with 
previous findings that from 2012 to 2016, EMS naloxone administrations and opioid overdose 
deaths had a bimodal age distribution at the national level (Cash et al., 2018). The major mode 
oscillates between the older and younger age groups; the older age group has the major mode in 
2009, 2010, 2013, and 2014, while the younger age group has the major mode in 2011 and 2017. 





Figure 5. Age Distribution of All Opioid-Involved Deaths by Year. 
 
Among FI cases, the bimodal distribution is apparent for several years in the study period, 
including 2009, 2010, and 2012, for which the major mode is the older age group. There is no 
apparent bimodality to 2013 or 2014. It is important to note that the total number of FI fatalities 
was quite small (n < 100) until 2015. The 2015-2017 bimodal distributions are subtle, but it 
appears the major mode is concentrated near the younger years for each of these final years, 
indicating that the fentanyl crisis is primarily among the young. This is consistent with previous 





Figure 6. Age Distribution of All Fentanyl-Involved Deaths by Year. 
 
4.2 Race & Ethnicity Distribution 
Across all years, white, non-Hispanic (W-NH) individuals made up 82.1% of all victims. In 
2009, the rate of OI deaths among the W-NH population (8.8 per 100,000) was about 2.3 times 
that of the black, non-Hispanic (B-NH) population (3.8 per 100,000) and 1.5 times that of the 
Hispanic, White (H-W) population (5.7 per 100,000).  
 
In 2017, the rate of OI deaths among the W-NH population (29.9 per 100,000) was about 1.6 
times the B-NH population (18.7 per 100,000) and 1.4 times that of the H-W population (21.6 




Figure 7. Opioid-Involved Deaths by Race.  
 
When compared to other race groups and adjusted for population size, W-NH individuals have 
consistently made up the majority of OI deaths across the study period. However, people of color 
do make up a sizable proportion of the epidemic. OI deaths among B-NH and among H-W 
individuals have increased in recent years, particularly since 2014. While W-NH deaths 
increased  212%  between 2013 and 2017, B-NH deaths increased by 267%, H-W deaths 
increased by 227%, and deaths among Other/Unknown races increased by 425%. Thus, the OI 
fatality crisis is accelerating at a faster rate among people of color.  
 
 
Figure 8. Fentanyl-Involved Deaths by Race.  
 
Similarly, although W-NH individuals remain the most represented race among FI deaths from 
2009 to 2017 (both by raw total and when adjusted for population size), mortality among people 




4.3 Sex Distribution 
Among all OI fatalities in CT, males have consistently been over-represented when compared to 
females, particularly after adjusting for CT’s population which has been approximately 5% more 
female across all study years (CT DPH, 2019). 
 
Across all study years, most victims were male (72.8%). The rate of OI deaths in males in 2009 
(10.8 per 100,000) was about 2.3 times that of females (4.6 per 100,000) in 2009, but it was 
about 3.3 times that of females in 2017. While OI fatalities increased among females by 274% 
from 2009 to 2017 , OI fatalities increased among males by 385% in the same time period. These 
findings indicate that the crisis is becoming more male over time. 
 
 
Figure 9. Opioid-Involved Deaths by Sex. 
 
 




Among FI fatalities, males have also been more highly represented. In 2017, males had 
approximately 4 times the incidence of females (30.3 versus 7.5 per 100,000), indicating the 
fentanyl problem is more male than the overall opioid crisis.  
 
4.4 Opioid Categories 
 
Overall, across all years, most OI fatalities involved illicit opioids (3417, 75.1%) compared to 
deaths that were caused by pharmaceutical opioids only (1067, 23.5%). The rate of fatalities due 
to pharmaceuticals only has remained relatively steadily over time while fentanyl-only deaths 
have increased sharply. Deaths involving a combination of opioid types have increased over this 
time period while heroin-only deaths have decreased since 2015 (Figure 11). These findings are 
consistent with the CDC’s description of the three waves of the epidemic, including the increase 
in heroin deaths after the reformulation of Oxycontin. 
 
 
Figure 11. Evolution of Opioid Types Represented in Opioid-Involved Deaths. 
 
When comparing 2009 to 2017, pharmaceutical only deaths have increased by 1.13 times and 
heroin only deaths have increased by 1.25 times. In contrast, fentanyl only deaths have increased 
by 40 times and combination deaths have increased by 6.3 times. In other words, 2017 looked a 
lot like 2009 with regard to heroin and pharmaceutical only fatalities, but with the addition of a 




In light of the recent increase in illicit fentanyl ​(Rudd et al. 2016)​, we sought to clarify whether 
the possibility of detection bias could have occurred over the period in question. According to 
the Chief Medical Examiner, fentanyl is routinely tested for and does not depend on positivity of 
an opioid screen. There has been no change in toxicology test procedures since 2009 that would 
explain the increase in detected FI deaths (Gill, 2019). However, many, but not all, fentanyl 




4.5 Spatial Patterns 
By raw total and across all years, the areas along the I-95 and I-91 corridors have been most 
heavily impacted by the opioid crisis. It seems that many of the most-impacted areas had opioid 
deaths in the earlier years of analysis and that the issue has intensified in these areas while 
spreading to new areas. For example, the Torrington and Norwich areas had two or more deaths 





Figure 12. All Opioid Fatalities for All Years by ZIP Code Tabulation Area (ZCTA), Raw Totals. 
 
Across all years when adjusted for population size, there are very few areas which have been left 
unscathed by the crisis (Figure 13). Interestingly, there are pockets of low incidence surrounding 
the high-incidence areas of Canaan and Torrington. Overall, although the crisis is often 
characterized as a rural issue, fatalities are still concentrated in urban areas even when 





Figure 13. All Opioid Fatalities for All Years by ZIP Code Tabulation Area (ZCTA) by 100,000 Population. ​Raw totals 






Figure 14. Space-Time Cube and Emerging Hot Spot Analysis of All Opioid-Involved Mortality. ​Consecutive Hot Spot: A 
single, uninterrupted run of hot time step intervals comprised of < 90% of all intervals; New Hot Spot: The most recent time step 
interval is hot for the first time; Not Emerging: No Trend; Oscillating Hot Spot: Some of the time step intervals are hot, some are 
cold; Sporadic Hot Spot: Some of the time step intervals are hot 
 
The space-time cube for all OI mortality used spatial bins that were 1,582 square meters and 
temporal bins of 6 months each (both calculated by default in ArcGIS), for a total of 18 time step 
intervals (bins). The space-time cube uses the Mann-Kendall test, a non-parametric method used 
to detect a trend in a series of values. Overall, there is a statistically significant increase in point 
counts over time for CT, and the trend direction is increasing with a Mann-Kendall trend statistic 
of 4.92 (p-value  <0.0001).  
 
Consecutive hot spots cover the areas of Hartford, Waterbury, Norwich, and New London, which 
means that those locations have seen an uninterrupted series of statistically significant hot spot 
bins in the final time-step intervals but none of them had been statistically significant hot spots 
prior to the start of the consecutive run. This designation is reserved for bins where under 90% of 






New Haven and Bridgeport are Sporadic Hot Spots, which means they have been statistically 
significant hot spots under 90% of the study period, but they have never been statistically 
significant cold spots (ArcGIS, 2018).  
 
The space-time cube for FI fatalities used larger spatial bins (1,928 square meters), also 
calculated by default in ArcGIS. The time step interval remained 6 months each for a total of 18 
time step intervals. For FI fatalities, there is a statistically significant increase in point counts 
over time and the overall trend direction is increasing with a Mann-Kendall trend statistic of 4.52 
(p-value <0.0001).  
 
Areas around Waterbury, Norwich, and New London are designated as consecutive hot spots, 
while Hartford, New Haven, and Bridgeport are oscillating hot spots. Oscillating hot spots are 
areas that are statistically significant hot spots for the final time-step interval but was historically 




Figure 15. Emerging Hotspot Analysis of Fentanyl-Involved Mortality. ​Consecutive Hot Spot: A single, uninterrupted run of 
hot time step intervals comprised of <90% of all intervals; New Hot Spot: The most recent time step interval is hot for the first 
time; Not Emerging: No Trend; Oscillating Hot Spot: Some of the time step intervals are hot, some are cold; Sporadic Hot Spot: 
Some of the time step intervals are hot 
5. Discussion 
5.1 Increase in Fentanyl-Involved Deaths 
Up until 2013, the number of cases involving fentanyl was relatively low and fairly stable over 
time with no more than 15 cases per year from 2009 to 2012. Beginning in 2013, we saw a sharp 
increase in the proportion of fentanyl-involved fatalities. Since then, the crisis has become more 
fentanyl-driven. The rate of fentanyl-involved deaths increased from 1.0 to 18.6 per 100,000 
population from 2013 to 2017. Among only fentanyl-involved deaths, victims were 
predominantly male (79.1%) with over half of all victims aged between 25 and 44. 
 
5.2 Implications 
The Trump Administration has secured $6 billion in funding to fight the opioid epidemic as of 
late 2018, with efforts focused on securing borders against smuggling and improving prescribing 
practices (White House, 2018).  
 
Efforts to reduce fentanyl overdose deaths specifically, including expanding access to testing 
strips and improving information dissemination regarding deadly batches, are needed to address 
the sharply rising number of fentanyl-involved deaths. In particular, males of all races under the 
age of 44 ought to be targeted by these interventions. Additionally, deploying EMS, increasing 
access to naloxone, and facilitating entry into medication-assisted treatment (MAT) programs in 
areas where fentanyl deaths are consistent or increasing, such as Norwich and New London, 
could go a long way to preventing future overdose deaths. 
 
Further, more attention ought to be paid to communities of color, where the rate of overdose 
deaths are outpacing those in white, non-Hispanic communities. 
 
5.3 Limitations 
This study is subject to several limitations. First, the choropleth maps tracking annual changes by 
ZCTA are normalized by 2010 population data, the only data which were available for the ZCTA 
enumeration unit. This prevents the maps from accurately reflecting population changes during 
the study period. Second, because analysis is confined to a single state, external validity is 
limited. However, the results reveal insights that may be useful to Connecticut-specific fatal 
overdose prevention initiatives. Third, although the CT OCME is a rich data source for fatalities 
in Connecticut, all information is limited to what is contained in the medical examiner’s reports. 
Occasionally, these are incomplete. Third, because there is no toxicological test which can 
25 
 
distinguish between all pharmaceutical forms of fentanyl and morphine and all illicit forms of 
fentanyl and morphine, we assumed that all toxicology reports with measured values of fentanyl 
or morphine were illicit. Lastly, because our  analysis did not include nonfatal overdoses, we 
underestimate the overall burden of overdose in Connecticut.  
6. Conclusion 
The epidemiology of fatal opioid overdose in CT exhibits distinct spatial, demographic, and 
temporal patterns. The recent increase in OI deaths can be attributed to fentanyl and fentanyl 
analogues, a finding which corresponds to the growing supply and use of illicitly manufactured 
fentanyl in the United States. Although much of the crisis has impacted white, non-Hispanic 
people, the burden on black, non-Hispanic and Hispanic, White populations continues to grow 
and outpace that of the white, non-Hispanic population. Additionally, fatalities among males are 
outpacing fatalities among females. Thus, future interventions ought to focus on preventing 
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